Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 63, Issue 2, Pages 281-287Publisher
SPRINGER
DOI: 10.1007/s00280-008-0738-2
Keywords
Nanoparticles; Emulsions; Breast cancer treatment; Drug targeting; Paclitaxel pharmacokinetics
Categories
Funding
- Fundacao do Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
Ask authors/readers for more resources
Purpose In animal experiments paclitaxel oleate associated with a cholesterol-rich nanoemulsion concentrated in the neoplastic tissues and showed reduced toxicity and increased antitumor activity compared with paclitaxel-Cremophor EL. Here, a clinical study was performed in breast cancer patients to evaluate the tumoral uptake, pharmacokinetics and toxicity of paclitaxel associated to nanoemulsions. Methods Twenty-four hours before mastectomy [H-3]paclitaxel oleate associated with [C-14]-cholesteryl oleatenanoemulsion or [H-3]- paclitaxel in Cremophor EL were injected into five patients for collection of blood samples and fragments of tumor and normal breast tissue. A pilot clinical study of paclitaxel-nanoemulsion administered at 3-week intervals was performed in four breast cancer patients with refractory advanced disease at 175 and 220 mg/m(2) dose levels. Results T-1/2 of paclitaxel oleate associated to the nanoemulsion was greater than that of paclitaxel (t(1/2) = 15.4 +/- 4.7 and 3.5 +/- 0.80 h). Uptake of the [C-14]-cholesteryl ester nanoemulsion and [H-3]- paclitaxel oleate by breast malignant tissue was threefold greater than the normal breast tissue and toxicity was minimal at the two dose levels. Conclusions Our results suggest that the paclitaxel-nanoemulsion preparation can be advantageous for use in the treatment of breast cancer because the pharmacokinetic parameters are improved, the drug is concentrated in the neoplastic tissue and the toxicity of paclitaxel is reduced.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available